Core Viewpoint - The company is actively adjusting its supply chain in response to the 20% tariff challenge and is focusing on high-barrier, high-margin products to maintain its competitive edge in the pharmaceutical industry [2][4]. Company Overview - The company, Jianyou Co., Ltd., is a pharmaceutical enterprise engaged in drug research, production, and sales, with a diverse product pipeline including cardiovascular, neurological, anesthetics, anti-tumor preparations, and high-value sterile injectables [4]. Financial Performance - In Q1 2025, the company reported a main revenue of 885 million yuan, a year-on-year decrease of 11.85% - The net profit attributable to shareholders was 84.71 million yuan, down 52.19% year-on-year - The net profit after deducting non-recurring gains and losses was 75.32 million yuan, a decline of 56.05% - The debt ratio stood at 26.38%, with investment income of 11.13 million yuan and financial expenses of 21.80 million yuan - The gross profit margin was 34.41% [4]. Product Development - The company’s biosimilar drugs are entering a harvest period, with liraglutide expected to receive FDA approval in April 2024, making the company the third globally to enter the market - Sales of adalimumab (Yusimry) have already surpassed 70 million yuan - Collaborations with Tonghua Dongbao and Double Star Pharmaceutical are progressing well, with a focus on insulin and paclitaxel products [4]. Market Strategy - The company views the U.S. market as a significant revenue source and plans to expand into Europe, the Middle East, and Central and South America by 2030, aiming to become a global enterprise [2][4]. Analyst Ratings - In the last 90 days, 9 institutions have given buy ratings for the stock, with an average target price of 19.21 yuan [5]. Profit Forecast - Detailed profit forecasts indicate expected net profits for 2025 ranging from 10.25 billion yuan to 12.18 billion yuan, with projections for 2026 and 2027 also showing growth [7]. Financing Activity - In the past three months, the stock has seen a net inflow of 52.81 million yuan in financing, with an increase in financing balance, while the net inflow of short selling was 953,600 yuan [7].

令人脊背发凉的是，黑客突破的归属用户服务器（HSS）系统本处于物理隔离的封闭网络，本被视作 "万无一失的保险柜"。但攻击者如鬼魅般潜入，导致USIM卡数据大规模泄露，涉及国际移动用户识别 码（IMSI）、电话号码及 21 种核心管理信息。韩国科学技术信息通信部（MSIT）调查发现，5台核心 服务器中暗藏4 款BPFDoor 病毒家族恶意软件，利用 Linux 系统伯克利数据包过滤器（BPF）漏洞悄然 渗透。技术专家指出，这类病毒的高隐蔽性让溯源追踪近乎 "大海捞针"，调查难度呈指数级攀升。 用户雪崩式流失，SK 电讯陷入 "生死时速" 韩国移动通信巨头SK电讯遭遇 "至暗时刻"！近日，SK电讯的系统遭到了黑客的恶意软件攻击，导致部 分用户的USIM相关信息泄露，韩国信息产业部部长刘尚任在紧急调研SK电讯总部后，言辞震惊："这 起事故已动摇公众对移动通信基础设施的根本信任！" 作为占据韩国5000万人口半数用户（2500 万）的 行业巨头，SK电讯首席执行官柳永相在国会听证会上坦言，此次SIM卡信息盗取案堪称电信行业历史 上最严重的黑客攻击，一场波及整个行业的信任风暴正在席卷而来。 铜墙铁壁被攻破：物理隔离系统 ...

来源：本文综合自Silvaco，谢谢。 Silvaco Group, Inc（"Silvaco"或"公司"）是一家 TCAD、EDA 软件和 SIP 解决方案提供商，通 过 AI 软件和创新实现半导体设计和数字孪生建模，今天宣布战略收购Tech-X Corporation，后者 是光子学、电磁学和等离子体动力学等应用中使用的多物理仿真软件的领先提供商。 Tech-X 尖端工具可以实现： 通过将 Tech-X 独特的多物理场仿真工具与 Silvaco 的 Victory TCAD 平台相结合，客户将能够 为光子学、半导体器件和晶圆级等离子蚀刻创建更精确的数字孪生模型，从而加速整个行业的创 新。Tech-X 为 Silvaco 带来了深厚的专业知识，开发了先进的算法，利用高性能、多节点的 GPU 计算，显著提高仿真速度和准确性。 如果您希望可以时常见面，欢迎标星收藏哦~ 随着 VSim 全球销量的增长，Tech-X 注意到 VSim 框架之外对其他产品的需求。2013 年，首个 版本的 USim（一款带电多流体仿真应用程序）面向消费者发售。最近，Tech-X 发布了 RSim， 这款产品源于 Tech-X 与 N ...

Core Viewpoint - SK Telecom, South Korea's largest carrier, is replacing mobile SIM chips for its 23 million users following a significant data breach that compromised personal information [3][4]. Group 1: Incident Overview - The data breach involved malicious code that led to the compromise of customer personal information, prompting an apology from the company and a government review of the national data protection system [4]. - SK Telecom has not disclosed the extent of the damage or the identity of the attackers [4]. Group 2: Response Actions - Starting from 10 am on Monday, SK Telecom began replacing USIM chips free of charge at 2,600 carrier stores nationwide [5]. - The company has committed to taking full responsibility and has encouraged users to sign up for an information protection service [5]. Group 3: Supply Chain Challenges - SK Telecom has acknowledged that it has secured less than 5% of the USIM cards needed for its customer base and plans to procure an additional five million chips by the end of May [6]. - Customers expressed concerns about the lack of transparency regarding the extent of the information leak and the number of affected subscribers [6]. Group 4: Cybersecurity Context - South Korea has been a frequent target of cyber hacking, particularly from North Korea, which has been implicated in several major attacks [7]. - In a related incident, North Korean hackers were reported to have stolen sensitive data from a South Korean court computer network over a two-year period, amounting to over one gigabyte of data [8].

根据《证券期货投资者适当性管理办法》及配套指引，本资料仅面向华创证券客户中的金融机构专业投资者，请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者，请勿订 阅、接收或使用本资料中的信息。 本资料难以设置访问权限，若给您造成不便，敬请谅解。感谢您的理解与配合。 摘要 高端注射剂平台建成，健友股份 3.0 To 2030 。 健友股份的前身健友生化厂于 1991 年成立，在创立以来三十余年的时间，公司始终保持 着前瞻的战略眼光和高效的执行力。目前健友股份产品管线丰富，业务涵盖无菌注射剂、肝素原料药、 CDMO 及生物药创新，立足中 美，拓展全球。回顾公司的发展历程，我们认为公司的成长模式和核心竞争力均已得到了较为充分的验证，并展现出广阔的成长空间。 原料药制剂一体化：肝素价稳筑基，制剂蓄势待发 。 健友股份作为国内肝素原料药及制剂一体化的龙头企业，凭借其在肝素产业链上的 完整布局，奠定了公司发展的坚实基础。公司不仅在肝素原料药领域占据重要地位，也通过制剂一体化战略，形成了从研发、生产到销 售的完整产业链条。 制剂出口 1 ：依诺肝素开篇，高端注射剂接力。 公司以依诺肝素制剂全球化突破为起点 ...

根据《证券期货投资者适当性管理办法》及配套指引，本资料仅面向华创证券客户中的金融机构专业投资者，请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者，请勿订 阅、接收或使用本资料中的信息。 本资料难以设置访问权限，若给您造成不便，敬请谅解。感谢您的理解与配合。 摘要 高端注射剂平台建成，健友股份 3.0 To 2030 。 健友股份的前身健友生化厂于 1991 年成立，在创立以来三十余年的时间，公司始终保持 着前瞻的战略眼光和高效的执行力。目前健友股份产品管线丰富，业务涵盖无菌注射剂、肝素原料药、 CDMO 及生物药创新，立足中 美，拓展全球。回顾公司的发展历程，我们认为公司的成长模式和核心竞争力均已得到了较为充分的验证，并展现出广阔的成长空间。 原料药制剂一体化：肝素价稳筑基，制剂蓄势待发 。 健友股份作为国内肝素原料药及制剂一体化的龙头企业，凭借其在肝素产业链上的 完整布局，奠定了公司发展的坚实基础。公司不仅在肝素原料药领域占据重要地位，也通过制剂一体化战略，形成了从研发、生产到销 售的完整产业链条。 制剂出口 1 ：依诺肝素开篇，高端注射剂接力。 公司以依诺肝素制剂全球化突破为起点 ...